SI2696889T1 - Variants of human GDNF - Google Patents
Variants of human GDNF Download PDFInfo
- Publication number
- SI2696889T1 SI2696889T1 SI201231134T SI201231134T SI2696889T1 SI 2696889 T1 SI2696889 T1 SI 2696889T1 SI 201231134 T SI201231134 T SI 201231134T SI 201231134 T SI201231134 T SI 201231134T SI 2696889 T1 SI2696889 T1 SI 2696889T1
- Authority
- SI
- Slovenia
- Prior art keywords
- seq
- variant
- human gdnf
- human
- rcgci
- Prior art date
Links
- 101150082979 gdnf gene Proteins 0.000 title 1
- 101000997829 Homo sapiens Glial cell line-derived neurotrophic factor Proteins 0.000 claims abstract 9
- 102000052654 human GDNF Human genes 0.000 claims abstract 9
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims abstract 3
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compounds Of Unknown Constitution (AREA)
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161474024P | 2011-04-11 | 2011-04-11 | |
| EP12712874.2A EP2696889B1 (en) | 2011-04-11 | 2012-04-03 | Variants of human gdnf |
| PCT/US2012/031927 WO2012141936A1 (en) | 2011-04-11 | 2012-04-03 | Variants of human gdnf |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2696889T1 true SI2696889T1 (en) | 2018-01-31 |
Family
ID=45932578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201231134T SI2696889T1 (en) | 2011-04-11 | 2012-04-03 | Variants of human GDNF |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9243046B2 (enExample) |
| EP (1) | EP2696889B1 (enExample) |
| JP (1) | JP6093345B2 (enExample) |
| KR (1) | KR101554799B1 (enExample) |
| CN (1) | CN103635201B (enExample) |
| AU (1) | AU2012243178B2 (enExample) |
| BR (1) | BR112013026004B1 (enExample) |
| CA (1) | CA2833158C (enExample) |
| CY (1) | CY1119750T1 (enExample) |
| DK (1) | DK2696889T3 (enExample) |
| EA (1) | EA025129B1 (enExample) |
| ES (1) | ES2656020T3 (enExample) |
| HR (1) | HRP20171993T1 (enExample) |
| HU (1) | HUE036239T2 (enExample) |
| IL (1) | IL228102A (enExample) |
| LT (1) | LT2696889T (enExample) |
| ME (1) | ME02849B (enExample) |
| MX (1) | MX337206B (enExample) |
| NO (1) | NO2696889T3 (enExample) |
| PL (1) | PL2696889T3 (enExample) |
| PT (1) | PT2696889T (enExample) |
| RS (1) | RS56639B1 (enExample) |
| SG (1) | SG193483A1 (enExample) |
| SI (1) | SI2696889T1 (enExample) |
| TW (1) | TWI583698B (enExample) |
| UA (1) | UA112981C2 (enExample) |
| WO (1) | WO2012141936A1 (enExample) |
| ZA (1) | ZA201306556B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7000349B2 (ja) | 2016-05-13 | 2022-02-04 | インスティテュート デ メディシナ モレキュラー ジョアオ ロボ アントゥネス | Ｉｌｃ３細胞に関連する疾患を処置する方法 |
| ES3036928T3 (en) * | 2019-12-19 | 2025-09-25 | Transfert Plus Soc En Commandite | Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies |
| JP2024522938A (ja) | 2021-06-03 | 2024-06-21 | フンダサン デー．アンナ ジ ソーメル チャンパリマウド エー ドクトル カルロス モンテス チャンパリマウド | 脳－脂肪回路を介してｉｌｃ２および肥満度を制御する神経－間葉単位 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9205293A (es) | 1991-09-20 | 1993-05-01 | Syntex Sinergen Neuroscience J | Factores neurotrofico derivado del glial |
| US6184200B1 (en) * | 1995-09-28 | 2001-02-06 | Amgen Inc. | Truncated glial cell line-derived neurotrophic factor |
| US6042579A (en) | 1997-04-30 | 2000-03-28 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain |
| DE19816186A1 (de) * | 1998-04-14 | 1999-10-21 | Univ Muenchen L Maximilians | GDNF-kodierende DNA, Teile davon und GDNF-Varianten |
| US8946151B2 (en) | 2003-02-24 | 2015-02-03 | Northern Bristol N.H.S. Trust Frenchay Hospital | Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen |
| FI20070808A0 (fi) * | 2007-10-25 | 2007-10-25 | Mart Saarma | GDNF:n silmukointivariantit ja niiden käytöt |
| CN101775072B (zh) * | 2008-05-21 | 2012-09-05 | 王尚武 | 一种融合穿透肽的神经细胞营养因子gdnf |
| AU2010211438B2 (en) * | 2009-02-06 | 2016-04-14 | Academisch Ziekenhuis Maastricht | Truncated cystine-knot proteins |
-
2012
- 2012-03-04 UA UAA201311714A patent/UA112981C2/uk unknown
- 2012-03-27 TW TW101110653A patent/TWI583698B/zh active
- 2012-04-03 SG SG2013069554A patent/SG193483A1/en unknown
- 2012-04-03 US US14/000,704 patent/US9243046B2/en active Active
- 2012-04-03 PT PT127128742T patent/PT2696889T/pt unknown
- 2012-04-03 AU AU2012243178A patent/AU2012243178B2/en not_active Ceased
- 2012-04-03 MX MX2013011919A patent/MX337206B/es active IP Right Grant
- 2012-04-03 HU HUE12712874A patent/HUE036239T2/hu unknown
- 2012-04-03 SI SI201231134T patent/SI2696889T1/en unknown
- 2012-04-03 ME MEP-2017-276A patent/ME02849B/me unknown
- 2012-04-03 WO PCT/US2012/031927 patent/WO2012141936A1/en not_active Ceased
- 2012-04-03 KR KR1020137026366A patent/KR101554799B1/ko not_active Expired - Fee Related
- 2012-04-03 LT LTEP12712874.2T patent/LT2696889T/lt unknown
- 2012-04-03 CA CA2833158A patent/CA2833158C/en not_active Expired - Fee Related
- 2012-04-03 HR HRP20171993TT patent/HRP20171993T1/hr unknown
- 2012-04-03 NO NO12712874A patent/NO2696889T3/no unknown
- 2012-04-03 JP JP2014505179A patent/JP6093345B2/ja active Active
- 2012-04-03 EP EP12712874.2A patent/EP2696889B1/en active Active
- 2012-04-03 ES ES12712874.2T patent/ES2656020T3/es active Active
- 2012-04-03 DK DK12712874.2T patent/DK2696889T3/en active
- 2012-04-03 CN CN201280018010.7A patent/CN103635201B/zh active Active
- 2012-04-03 EA EA201370204A patent/EA025129B1/ru not_active IP Right Cessation
- 2012-04-03 RS RS20171274A patent/RS56639B1/sr unknown
- 2012-04-03 BR BR112013026004-1A patent/BR112013026004B1/pt not_active IP Right Cessation
- 2012-04-03 PL PL12712874T patent/PL2696889T3/pl unknown
-
2013
- 2013-08-22 IL IL228102A patent/IL228102A/en active IP Right Grant
- 2013-08-30 ZA ZA2013/06556A patent/ZA201306556B/en unknown
-
2018
- 2018-01-09 CY CY20181100021T patent/CY1119750T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2011000343A (es) | Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral | |
| MX2012007410A (es) | Compuestos antivirales novedosos. | |
| EP4600271A3 (en) | Bioactive molecule conjugate, preparation method and use thereof | |
| IL273194B2 (en) | Methods, compounds and compositions for treatment of parainfluenza virus in immunocompromised patients | |
| BR112014007902A2 (pt) | composições farmacêuticas compreendendo 40-o-(2-hidróxi)etil-rapamicina | |
| BR112012016853A2 (pt) | "composições farmacêuticas para administração oral de peptídeos de insulina". | |
| BR112014007532A2 (pt) | variantes do fator de crescimento de fibroblastos 21 | |
| MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
| JP2014530220A5 (enExample) | ||
| CO6670598A2 (es) | Forma de dosificación resistente a alteración que comprende un polímero aniónico | |
| SI2709613T1 (en) | Procedures for the treatment of HCV | |
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| FI3494972T3 (fi) | Dolutegraviirin ja lamivudiinin yhdistelmiä hiv-infektion hoitoon | |
| UY32599A (es) | Formulación oral sólida de abt-263 | |
| WO2011110655A3 (en) | Immunogenic composition or vaccine against gram - negative bacterial, for example neiserial, infection or disease | |
| BR112015007366A2 (pt) | derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças | |
| AR081948A2 (es) | USO DE b DEFENSINAS DE MAMIFEROS PARA LA MANUFACTURA DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS DEL INTESTINO | |
| BR112015010396A2 (pt) | terapia de combinação | |
| JP2011225596A5 (enExample) | ||
| BR112012015202A2 (pt) | "iota - e/ou kappa-carrgenado junto com um inibidor da neuraminidase, método para o tratamento profilático ou terapêutico de um sintoma, condição ou doença, composição farmacêutica,e, kit de partes". | |
| BRPI0920605A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para o tratamento ou profilaxia de infecção pelo hiv ou para o tratamento, profilaxia, ou retardo no início ou progressão da aids em um paciente em necessidade deste. | |
| WO2012093234A3 (fr) | Arabinogalactanes sulfates, apiogalacturonanes et heteroglycanes sulfates pour le traitement des maladies causees par les virus influenza | |
| HRP20211749T1 (hr) | Pentanske kiseline supstituirane pirolo-[2-3,b]pirimidin-piridinima za liječenje virusnih infekcija influencom | |
| ES2429422R1 (es) | Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH | |
| UA109414C2 (uk) | Арильовані камфени та фармацевтична композиція на їх основі |